Select Page

We are excited to announce that CSOFT Health Sciences will be participating in the DIA 2024 Global Annual Meeting this June. This prestigious event provides us with a great opportunity to demonstrate our dedication to advancing the life sciences industry, especially in areas  crucial to shaping the future of healthcare, such as patient diversity, decentralized clinical trials (DCTs), and the integration of generative AI in pharmaceutical development. 

Embracing Patient Diversity: A Core Focus 

The landscape of clinical trials is evolving rapidly, and at the forefront of this transformation is the imperative for patient diversity. The FDA’s April 2023 guidance on voluntary diversity action plans, coupled with the mandates from the 2023 Omnibus spending bill (Public Law 117-328), underscores the importance of inclusive clinical trials. Starting Q2 2024, diversity action plans will be mandatory for all clinical trial submissions to the FDA.  

CSOFT Health Sciences is uniquely positioned to support this shift. Our expertise in language services and patient outreach enables us to effectively engage underrepresented communities, ensuring that clinical trials reflect the diverse populations they aim to serve. Throughout the DIA event, we have highlighted numerous sessions focused on Diversity, Equity, and Inclusion (DEI), as we believe our role in facilitating these initiatives will be crucial for the industry’s compliance and success.  

Linguistic Validation: Ensuring Accuracy and Cultural Relevance 

Our dedication to including a diverse range of patients and conducting trials in various locations involves carefully validating translated materials. This process ensures that the translations are not only accurate but also easy for people from diverse cultures to understand. We use back-translation and cognitive debriefing to check that documents like consent forms and questionnaires are clear and culturally appropriate for patients. This thorough validation process is essential for maintaining the quality of clinical trials and making sure that patients from diverse backgrounds feel engaged. 

Decentralized Clinical Trials: Enhancing Accessibility and Inclusion 

Decentralized Clinical Trials (DCTs) are transforming the way clinical research is conducted, making it more accessible and inclusive. At CSOFT, we recognize the significant potential of DCTs to improve patient diversity and are actively involved in several key aspects of this innovative approach: 

  • Telemedicine: Our innovative online translation services ensure that language barriers do not impede patient participation, allowing for real-time, multilingual telemedicine consultations. 
  • Electronic Informed Consent (eICF): We provide seamless translation and localization of electronic informed consent forms, ensuring that patients fully understand the research protocols and their rights, regardless of their native language. 
Harnessing Generative AI for Accelerated Development 

The use of generative AI in the pharmaceutical industry is a major focus at this year’s DIA meeting. There are numerous sessions dedicated to its application in accelerating and improving product development. Generative AI has the potential to revolutionize various stages of the drug development process, from early-stage research to clinical trials and beyond. 

CSOFT Health Sciences is at the forefront of leveraging generative AI to enhance precision and efficiency in pharmaceutical development. Our solutions are designed to streamline processes, reduce timelines, and improve the overall quality of drug development, ensuring that innovative therapies reach patients faster. 

 Join Us at Booth #1611 

We invite all attendees of the DIA 2024 Global Annual Meeting to visit us at Booth 1611. Here, you can learn more about how CSOFT Health Sciences is driving advancements in patient diversity, decentralized clinical trials, and the use of generative AI in the pharmaceutical industry. Our team of experts will be on hand to discuss our comprehensive suite of services and explore how we can collaborate to overcome the challenges and seize the opportunities ahead. 

Together, let’s shape a more inclusive and innovative future for global health sciences.   

See you at DIA 2024!